Kymera Therapeutics presented new preclinical data for KT-579, an oral IRF5 degrader, showing it effectively modulates multiple inflammatory pathways in inflammatory bowel disease (IBD) models. KT-579 demonstrated comparable or superior activity to existing therapies by reducing key inflammatory cytokines and improving disease markers. The drug is currently in a Phase 1 trial with healthy volunteers, focusing on safety and IRF5 degradation, with results expected in the second half of 2026. This novel oral treatment could offer a new option for patients with complex autoimmune diseases like IBD.
The Schall Law Firm has launched an investigation into Oxford Industries following the company's sharp revenue guidance cut on June 10, 2026, which caused a significant drop in its share price. The probe focuses on whether Oxford issued false or misl...
The global market for highway, street, and bridge construction is projected to grow from $1.28 trillion in 2025 to $2.18 trillion by 2035, at a compound annual growth rate of 4.8%. Growth is driven by government infrastructure spending, urbanization,...
Pepeto's presale has rapidly raised over $10.27 million as Bitcoin's price surges past $66,600, fueled by positive market events like the US-Iran ceasefire and renewed ETF inflows. Cathie Wood's bullish Bitcoin price prediction of $1.25 million by 20...
Alibaba is reportedly offering $1.5 billion to acquire Pupu, a dominant online grocer in South China's Fujian province, more than double the $717 million Meituan paid for Dingdong, a national online grocer. This move highlights the fierce competition...
The Freelander 8, a luxury electric vehicle, made its public debut at the Abu Dhabi Investment Forum's Shanghai session on June 11, 2026, ahead of its official launch in Abu Dhabi. This debut highlights Freelander's strategic entry into the Middle Ea...
